Antimicrobial peptides as drugs with double response against Mycobacterium tuberculosis coinfections in lung cancer

被引:7
|
作者
Polinario, Giulia [1 ]
Primo, Laura Maria Duran Gleriani [1 ]
Rosa, Maiara Alane Baraldi Cerquetani [1 ]
Dett, Freddy Humberto Marin [1 ]
Barbugli, Paula Aboud [1 ]
Roque-Borda, Cesar Augusto [2 ]
Pavan, Fernando Rogerio [1 ]
机构
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Araraquara, SP, Brazil
[2] Univ Catolica Santa Maria UCSM, Vicerrectorado Invest, Arequipa, Peru
基金
巴西圣保罗研究基金会;
关键词
Mycobacterium tuberculosis; lung cancer; peptides; multifunctional peptides; treatment; BETA-DEFENSIN; 2; INFLAMMATION; MICROBIOME; MECHANISM; CELLS; HOST; THERAPEUTICS; EPIREGULIN; EXPRESSION; RESISTANT;
D O I
10.3389/fmicb.2023.1183247
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Tuberculosis and lung cancer are, in many cases, correlated diseases that can be confused because they have similar symptoms. Many meta-analyses have proven that there is a greater chance of developing lung cancer in patients who have active pulmonary tuberculosis. It is, therefore, important to monitor the patient for a long time after recovery and search for combined therapies that can treat both diseases, as well as face the great problem of drug resistance. Peptides are molecules derived from the breakdown of proteins, and the membranolytic class is already being studied. It has been proposed that these molecules destabilize cellular homeostasis, performing a dual antimicrobial and anticancer function and offering several possibilities of adaptation for adequate delivery and action. In this review, we focus on two important reason for the use of multifunctional peptides or peptides, namely the double activity and no harmful effects on humans. We review some of the main antimicrobial and anti-inflammatory bioactive peptides and highlight four that have anti-tuberculosis and anti-cancer activity, which may contribute to obtaining drugs with this dual functionality.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Protein Kinase Inhibitors as Potential Antimicrobial Drugs Against Tuberculosis, Malaria and HIV
    Cheng, Yong
    Schorey, Jeffrey S.
    Zhang, Cheng-Cai
    Tan, Xuejuan
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (29) : 4369 - 4389
  • [42] Antimicrobial peptides: a promising strategy for lung cancer drug discovery?
    Zandsalimi, Farshid
    Talaei, Sam
    Noormohammad Ahari, Mehdi
    Aghamiri, Shahin
    Raee, Pourya
    Roshanzamiri, Soheil
    Yarian, Fatemeh
    Bandehpour, Mojgan
    Zohrab Zadeh, Zeinab
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (11) : 1343 - 1354
  • [43] Blood agar for susceptibility testing of Mycobacterium tuberculosis against first-line drugs
    Coban, AY
    Cihan, CC
    Bilgin, K
    Uzun, M
    Akgunes, A
    Cetinkaya, E
    Durupinar, B
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2006, 10 (04) : 450 - 453
  • [44] Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis
    Nakahama, Kenji
    Kaneda, Hiroyasu
    Ogawa, Koichi
    Matsumoto, Yoshiya
    Tani, Yoko
    Suzumura, Tomohiro
    Mitsuoka, Shigeki
    Watanabe, Tetsuya
    Asai, Kazuhisa
    Kawaguchi, Tomoya
    INTERNAL MEDICINE, 2022, 61 (07) : 1039 - 1042
  • [45] 1,4-Benzoquinone antimicrobial agents against Staphylococcus aureus and Mycobacterium tuberculosis derived from scorpion venom
    Norberto Carcamo-Noriega, Edson
    Sathyamoorthi, Shyam
    Banerjee, Shibdas
    Gnanamani, Elumalai
    Mendoza-Trujillo, Monserrat
    Mata-Espinosa, Dulce
    Hernandez-Pando, Rogelio
    Ignacio Veytia-Bucheli, Jose
    Possani, Lourival D.
    Zare, Richard N.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (26) : 12642 - 12647
  • [46] Improved Cellular Immune Response Elicited by a Ubiquitin-Fused DNA Vaccine Against Mycobacterium tuberculosis
    Wang, Qingmin
    Lei, Chengxiang
    Wan, Hui
    Liu, Qiuhong
    DNA AND CELL BIOLOGY, 2012, 31 (04) : 489 - 495
  • [47] Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates
    Zou, Lin
    Liu, Min
    Wang, Yufeng
    Lu, Jie
    Pang, Yu
    TUBERCULOSIS, 2015, 95 (06) : 839 - 842
  • [48] Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis
    Rao, Martin
    Valentini, Davide
    Zumla, Alimuddin
    Maeurer, Markus
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 69 : 78 - 84
  • [49] Host Cell Death and Modulation of Immune Response against Mycobacterium tuberculosis Infection
    Vu, Annie
    Glassman, Ira
    Campbell, Giliene
    Yeganyan, Stephanie
    Nguyen, Jessica
    Shin, Andrew
    Venketaraman, Vishwanath
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [50] For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection
    Dorhoi, Anca
    Reece, Stephen T.
    Kaufmann, Stefan H. E.
    IMMUNOLOGICAL REVIEWS, 2011, 240 : 235 - 251